Objective: This study compares surgical and survival outcomes of women with stage IV uterine serous carcinoma (USC) treated with neoadjuvant chemotherapy (NAC) and interval cytoreduction to women treated with primary cytoreductive surgery (PCS) followed by adjuvant chemotherapy. Methods: This retrospective dual cohort study included women diagnosed with stage IV USC at a single academic institution. Kruskal-Wallis and Fisher exact tests were used to compare demographics and surgical outcomes. Progression-free survival (PFS) and overall survival (OS) were estimated by using Kaplan-Meier methods. Comparison between study groups was tested by log-rank statistics. Results: Ten women with stage IV USC who received NAC and 34 who underwent PCS met inclusion criteria. Neoadjuvant chemotherapy patients had a lower mean body mass index and were more often African American. Compared with PCS, the NAC cohort had shorter mean operative times (137 T 66 vs 203 T 80 minutes, P = 0.025) and were discharged from the hospital earlier (median length of stay, 3 vs 5 days; P = 0.002). Rates of debulking to no gross residual disease (70%NAC vs 32.3% PCS) or less than 1 cm of disease (30%NAC vs 50%PCS) did not differ (P= 0.10).Median follow-up timewas 17.5months. Therewas no difference inmedian PFS (10.4 vs 12months, P = 0.29) or OS (17.3 vs 20.7 months, P = 0.23) for NAC and PCS cohorts. Conclusions: Women receiving NAC for stage IV USC had shorter surgeries and hospital stays than did those receiving PCS. There was no difference in PFS or OS, although our sample size was small. Neoadjuvant chemotherapy may be an appropriate therapy for select patients with advanced-stage USC.

Original languageEnglish
Pages (from-to)63-68
Number of pages6
JournalInternational Journal of Gynecological Cancer
Issue number1
StatePublished - Jan 1 2015


  • Endometrial carcinoma
  • Neoadjuvant chemotherapy
  • Uterine serous carcinoma


Dive into the research topics of 'Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage iv uterine serous carcinoma'. Together they form a unique fingerprint.

Cite this